Dianthus Therapeutics Cash Flow Statement
NASDAQ: DNTHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
82.37-0.06 (-0.07%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Dianthus Therapeutics free cash flow
In fiscal 2025, Dianthus Therapeutics generated -$129.1 million of operating cash flow and spent $213,000 on capital expenditures. That left free cash flow of -$129.3 million, a free-cash-flow margin of -6349.4% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Dianthus Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -162.34M | -84.97M | -43.55M | -28.48M | -71.14M | -74.94M | -76.77M | -57.52M | -35.49M | -9.43M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 111.00K | 96.00K | 67.00K | 1.93M | 2.02M | 1.98M | 1.84M | 875.00K | 376.00K | 6.00K |
| Stock-Based Compensation | 22.79M | 12.89M | 2.90M | 1.52M | 10.31M | 9.94M | 10.00M | 10.70M | 2.26M | 662.00K |
| Change in Working Capital | 4.88M | -5.78M | -1.03M | 59.00K | -1.79M | 2.37M | -1.22M | 689.00K | -2.02M | 965.00K |
| Operating Cash Flow | -129.06M | -78.18M | -36.86M | -29.07M | -59.53M | -64.02M | -57.10M | -41.89M | -22.26M | -6.53M |
| Capital Expenditures | -213.00K | -105.00K | -110.00K | -314.00K | -1.26M | -400.00K | -3.06M | -7.67M | -2.20M | -139.00K |
| Investing Cash Flow | -122.83M | -286.81M | 20.25M | -59.82M | 43.43M | -10.63M | 1.53M | -91.70M | -2.20M | -139.00K |
| Financing Cash Flow | 280.13M | 255.62M | 133.57M | 96.68M | 89.60M | 67.74M | 62.30M | 142.15M | 71.49M | 10.71M |
| Net Change in Cash | 28.23M | -109.37M | 116.97M | 7.79M | 73.50M | -6.92M | 6.73M | 8.56M | 47.02M | 4.04M |
| Free Cash Flow | -129.27M | -78.28M | -36.97M | -29.38M | -60.80M | -64.42M | -60.16M | -49.56M | -24.46M | -6.67M |
This table shows 10 annual periods of Dianthus Therapeutics's cash flow statement, from FY 2025 back to FY 2016, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow DNTH's reporting calendar. What is a cash flow statement?